Subtype
WHO Grade 2 Glioma
CI-CAN-00007115Explore in graph →
Non-malignant84 active trials28 evidence items
- NCIt
- C132505
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00007115Explore in graph →
Clinical trials
255 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03969706 | Abemaciclib in Patients With Oligodendroglioma | completed | Phase 2 | 10 | Stephen Bagley, MD, MSCEOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT03194906 | Memantine for Prevention of Cognitive Late Effects in Pediatric Patients Receiving Cranial Radiation Therapy for Localized Brain Tumors | completed | Phase 2 | 41 | St. Jude Children's Research HospitalOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT03213678 | Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 18 | National Cancer Institute (NCI)NIH | 2 | Apr 21, 2026 | clinicaltrials |
| NCT03213665 | Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 2 | Apr 13, 2026 | clinicaltrials |
| NCT03526250 | Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 23 | National Cancer Institute (NCI)NIH | 2 | Apr 3, 2026 | clinicaltrials |
| NCT06439420 | CBT-I in Primary Brain Tumor Patients: Phase IIc Randomized Feasibility Pilot Trial(CBT-I in PBT) | completed | Phase 2 | 70 | Virginia Commonwealth UniversityOTHER | 1 | Oct 1, 2025 | clinicaltrials |
| NCT01295944 | Carboplatin and Bevacizumab for Recurrent Ependymoma | completed | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | Aug 5, 2025 | clinicaltrials |
| NCT01288235 | Proton Radiotherapy for Pediatric Brain Tumors Requiring Partial Brain Irradiation | completed | Phase 2 | 100 | Massachusetts General HospitalOTHER | 1 | Jun 3, 2025 | clinicaltrials |
| NCT03220035 | Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 4 | National Cancer Institute (NCI)NIH | 2 | Jan 27, 2025 | clinicaltrials |
| NCT03914742 | BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations | completed | Phase 1 / Phase 2 | 67 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jan 14, 2025 | clinicaltrials |
| NCT03233204 | Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 6 | National Cancer Institute (NCI)NIH | 2 | Dec 11, 2024 | clinicaltrials |
| NCT02530320 | Safety and Efficacy of PD0332991 (Palbociclib), a Cyclin-dependent Kinase 4 and 6 Inhibitor, in Patients With Oligodendroglioma or Recurrent Oligoastrocytoma Anaplastic With the Activity of the Protein RB Preserved | completed | Phase 2 | 34 | Grupo Español de Investigación en NeurooncologíaOTHER | 1 | Nov 22, 2024 | clinicaltrials |
| NCT02155920 | Everolimus for Children With Recurrent or Progressive Ependymoma | completed | Phase 2 | 11 | University of Texas Southwestern Medical CenterOTHER | 1 | May 8, 2024 | clinicaltrials |
| NCT02684058 | Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors | completed | Phase 2 | 151 | Novartis PharmaceuticalsINDUSTRY | 20 | Dec 13, 2023 | clinicaltrials |
| NCT01609790 | Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors | completed | Phase 2 | 137 | National Cancer Institute (NCI)NIH | 2 | Jul 21, 2022 | clinicaltrials |
| NCT00303849 | Carboplatin, Melphalan, Etoposide Phosphate, Mannitol, and Sodium Thiosulfate in Treating Patients With Previously Treated Brain Tumors | completed | Phase 1 / Phase 2 | 33 | OHSU Knight Cancer InstituteOTHER | 1 | Mar 17, 2022 | clinicaltrials |
| NCT01051557 | Temsirolimus and Perifosine in Treating Patients With Recurrent or Progressive Malignant Glioma | completed | Phase 1 / Phase 2 | 36 | National Cancer Institute (NCI)NIH | 1 | Jul 19, 2021 | clinicaltrials |
| NCT01125046 | Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas | completed | Phase 2 | 50 | Northwestern UniversityOTHER | 1 | Jan 22, 2021 | clinicaltrials |
| NCT01024907 | Proton Beam Radiation Therapy in Treating Patients With Low Grade Gliomas | completed | Phase 1 / Phase 2 | 23 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Dec 10, 2020 | clinicaltrials |
| NCT01635283 | Vaccine for Patients With Newly Diagnosed or Recurrent Low-Grade Glioma | completed | Phase 2 | 5 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Nov 4, 2020 | clinicaltrials |
| NCT00823459 | Everolimus in Treating Patients With Recurrent Low-Grade Glioma | completed | Phase 2 | 58 | Susan ChangOTHER | 1 | Jul 28, 2020 | clinicaltrials |
| NCT00049127 | Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor | completed | Phase 1 / Phase 2 | 64 | Alliance for Clinical Trials in OncologyOTHER | 1 | Oct 21, 2019 | clinicaltrials |
| NCT01514201 | Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine Gliomas | completed | Phase 1 / Phase 2 | 66 | National Cancer Institute (NCI)NIH | 1 | Aug 13, 2019 | clinicaltrials |
| NCT00749723 | Therapy Optimization Trial for the Treatment of Relapsed or Refractory Brain Tumors in Children(HIT-REZ-2005) | completed | Phase 2 / Phase 3 | 174 | University Hospital, BonnOTHER | 1 | Jul 20, 2018 | clinicaltrials |
| NCT00362570 | Temozolomide in Patients With Newly Diagnosed Anaplastic Oligodendroglioma and Mixed Oligoastrocytoma | completed | Phase 2 | 1 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Nov 30, 2017 | clinicaltrials |
| NCT00381797 | Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma | completed | Phase 2 | 97 | National Cancer Institute (NCI)NIH | 1 | Nov 28, 2017 | clinicaltrials |
| NCT00392171 | The Effects of Continuous 28-day (28/28) Temozolomide Chemotherapy in Subjects With Recurrent Malignant Glioma Who Have Failed the Conventional 5-day (5/28) Treatment (P04601) | completed | Phase 2 | 120 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jun 7, 2017 | clinicaltrials |
| NCT00499473 | Sunitinib in Treating Patients With Recurrent Malignant Gliomas | completed | Phase 2 | 31 | National Cancer Institute (NCI)NIH | 1 | Feb 29, 2016 | clinicaltrials |
| NCT01462695 | Sunitinib Malate in Treating Younger Patients With Recurrent, Refractory, or Progressive Malignant Glioma or Ependymoma | completed | Phase 2 | 30 | National Cancer Institute (NCI)NIH | 3 | Aug 27, 2015 | clinicaltrials |
| NCT00112736 | Erlotinib and Temsirolimus in Treating Patients With Recurrent Malignant Glioma | completed | Phase 1 / Phase 2 | 69 | National Cancer Institute (NCI)NIH | 1 | Jun 15, 2015 | clinicaltrials |
| NCT00042991 | Gefitinib and Radiation Therapy in Treating Children With Newly Diagnosed Gliomas | completed | Phase 1 / Phase 2 | 69 | National Cancer Institute (NCI)NIH | 1 | May 28, 2014 | clinicaltrials |
| NCT00095940 | Lapatinib in Treating Young Patients With Recurrent or Refractory Central Nervous System Tumors | completed | Phase 1 / Phase 2 | 52 | National Cancer Institute (NCI)NIH | 1 | May 23, 2014 | clinicaltrials |
| NCT00492089 | Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer | completed | Phase 2 | 11 | National Cancer Institute (NCI)NIH | 1 | May 9, 2014 | clinicaltrials |
| NCT00575887 | Efficacy of Protracted Temozolomide in Patients With Progressive High Grade Glioma | completed | Phase 2 | 25 | Marmara UniversityOTHER | 1 | Dec 20, 2013 | clinicaltrials |
| NCT00070525 | Tipifarnib in Treating Young Patients With Recurrent or Progressive High-Grade Glioma, Medulloblastoma, Primitive Neuroectodermal Tumor, or Brain Stem Glioma | completed | Phase 2 | 90 | National Cancer Institute (NCI)NIH | 1 | Oct 8, 2013 | clinicaltrials |
| NCT00004078 | Irinotecan in Treating Children With Refractory Solid Tumors | completed | Phase 2 | 181 | Children's Oncology GroupNETWORK | 1 | Jun 14, 2013 | clinicaltrials |
| NCT00091182 | Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment | completed | Phase 2 | 180 | National Cancer Institute (NCI)NIH | 1 | Jun 5, 2013 | clinicaltrials |
| NCT00520936 | A Study of Pemetrexed in Children With Recurrent Cancer | completed | Phase 2 | 72 | Eli Lilly and CompanyINDUSTRY | 1 | Feb 25, 2011 | clinicaltrials |
| NCT00165360 | Prolonged Daily Temozolomide for Low-Grade Glioma | completed | Phase 2 | 46 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 2, 2009 | clinicaltrials |
Data updated 5 days agoSource updated Sep 25, 2026source: clinicaltrials